| ID | 1292 |
| Name of the vaccine | Tetrabik |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 6 to 11 weeks |
| Description of the vaccine | DTP-IPV vaccine used as part of the Japanese vaccination schedule. |
| Name of the manufacturer | Merck Sharp & Dohme Corp. |
| Name of the manufacturing country | NA |
| Year of manufacture | 2014 |
| Clinical Phase status | Clinical - Phase 4 |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Three doses of 0.5 mL. |
| Mechanism of action | NA |
| Route of administration | Subcutaneous |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For diphtheria, tetanus, pertussis and inactivated poliovirus. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT01926015 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|